Airain Ltd’s Pacific Biosciences PACB Stock Holding History

Airain Ltd’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-34,400	Closed	-$308K	–	808
2016 Q3	$308K	Buy	+34,400	New	+$288K	0.02%	499
2016 Q1	–	Sell	-17,082	Closed	-$224K	–	999
2015 Q4	$224K	Buy	+17,082	New	+$153K	0.02%	692
2014 Q2	–	Sell	-30,437	Closed	-$163K	–	881
2014 Q1	$163K	Buy	+30,437	New	+$192K	0.03%	618

Other funds holding PACB

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Airain Ltd's PACB Position: Q4 2016 in Review

Airain Ltd sold out of Pacific Biosciences (PACB) in Q4 2016, closing a stake of 34,400 shares — an estimated $308K sold.

Airain Ltd first reported a position in PACB in Q1 2014 and held it in 3 quarters. The position peaked at $308K in Q3 2016. 115 funds tracked by Wall St. Rank hold PACB as of Q4 2016.

Airain Ltd reported no remaining Pacific Biosciences position as of Q4 2016 after selling out during the quarter.
Airain Ltd sold 34,400 Pacific Biosciences shares in Q4 2016, an estimated $308K.
Airain Ltd first reported a position in Pacific Biosciences in Q1 2014 and held it in 3 quarters.
Airain Ltd's Pacific Biosciences position peaked at $308K in Q3 2016.
115 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2016.

Based on Airain Ltd's 13F filing for Q4 2016, filed 10 Feb 2017.